



## IN8bio to Present at TD Cowen 46th Annual Health Care Conference

February 24, 2026

NEW YORK, Feb. 24, 2026 (GLOBE NEWSWIRE) -- [IN8bio, Inc.](#) (Nasdaq: INAB), a clinical-stage biopharmaceutical company developing innovative gamma-delta ( $\gamma\delta$ ) T cell therapies for cancer and autoimmune diseases, today announced that William Ho, CEO and co-founder, will be presenting at the TD Cowen 46<sup>th</sup> Annual Health Care Conference on Monday, March 2, at 9:50 am ET.

William Ho will be giving a company presentation highlighting IN8bio's latest achievements and upcoming milestones. The conference, to be held March 2-4, 2026, in Boston, will also include one-on-one investor meetings hosted by members of management.

A live webcast and replay link for the TD Cowen conference can be [found here](#), and will be available under "Events and Presentations" in the News & Presentations section of the IN8bio website at <https://investors.in8bio.com>.

### About IN8bio

IN8bio is a clinical-stage biopharmaceutical company developing  $\gamma\delta$  T cell therapeutic and  $\gamma\delta$  T cell engager (TCE) product candidates to address unmet medical needs.  $\gamma\delta$  T cells are a specialized population of T cells that possess unique properties, including the ability to differentiate between healthy and diseased tissue. The Company's lead programs consist of INB-100, an allogeneic  $\gamma\delta$  T cell candidate for adult patients with high-risk leukemias undergoing haploidentical stem cell transplantation. The Company is also developing INB-200/400, an autologous genetically modified  $\gamma\delta$  T cell candidate for newly diagnosed Glioblastoma (GBM). The preclinical pipeline includes a novel  $\gamma\delta$  T cell engager platform, INB-600, which activates and expands  $\gamma\delta$  T cells in vivo for deep target cell depletion and is being developed for oncology and autoimmune indications. For more information about IN8bio, visit [www.IN8bio.com](http://www.IN8bio.com).

### Investors & Company Contacts:

#### IN8bio, Inc.

Patrick McCall

646.933.5603

[pfmccall@IN8bio.com](mailto:pfmccall@IN8bio.com)

#### Media Contact

Kimberly Ha

KKH Advisors

917.291.5744

[kimberly.ha@kxhadvisors.com](mailto:kimberly.ha@kxhadvisors.com)